Are PDEX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PDEX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Stock Ratings / Health Care / PDEX / insiders

STIM (28) KTWO (56) UTMD (62) PROF (40) ⌘ Pro Terminal →

Pro-Dex Inc. (PDEX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$57.65 -0.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $57.45

Pro-Dex Inc. (PDEX) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $186.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PDEX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PDEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Pro-Dex Inc. (NASDAQ: PDEX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $57.65 (-0.88% 1D, market cap $186.1M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, PDEX ranks #220 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PDEX compare to STIM and KTWO in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), PDEX carries a Roarable D+ (54/100 RQD), trailing P/E of 22.2x, gross margin of 29.3%, and ROIC of 23.2%. By comparison, STIM (Neuronetics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $171.4M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $202.2M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PDEX?

▼

Per PDEX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000788920), Pro-Dex Inc. generated $66.6M in revenue (+23.7% YoY), $9.0M in net income, and -$2.9M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $57.45 (-0.35%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PDEX)Realized 20D OHLCV Swing Band: ±9.4%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY PDEX SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (30% of score)

Altman Z-Score 9.08 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+11/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 29.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$62.27-4.6% Next Q

Q2 (-2Q)

Grade C$59.40+4.8% Next Q

Q3 (-1Q)

Grade C$62.27-7.4% Next Q

Current

Grade D+$57.65-0.7% Hist 90D α

Trajectory: C+ (62) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PDEX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PDEX currently carries a cautious 54/100 (D+) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($64.51) and Max Pain ($60.53) forces dealer call-delta covering toward $80.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PDEX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PDEX Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PDEX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PDEX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PDEX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PDEX)

✓Walkthrough of PDEX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PDEX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.53%🛡️ HOLDING TREND SUPPORT

2026-11-03O $61.60H $61.60L $57.65C $57.65VOL 38.5K

RES: $81.98SUP: $56.53SMA50: $64.51SMA200: $56.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PDEX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PDEX Butterfly Map → + Track PDEX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

15.9%/yr Implied 5Y Growth

vs. +23.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PDEX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PDEX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PDEX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PDEX)

Health Care Rank #220 of 1015 ⚔️ STIM vs PDEX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PDEX vs. STIM, KTWO, UTMD, PROF)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pro-Dex Inc. (PDEX) ranks #220 by composite RQD confidence (54/100, grade D+) and #582 by equity capitalization ($186.1M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with PDEX at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PDEX ACTIVE Pro-Dex Inc.	D+	54/100	22.2x	29.3%	23.2%	-0.88%	$186.1M	Benchmark Subject
STIM Neuronetics Inc.	E	28/100	—	48.5%	-35.0%	-8.44%	$171.4M	/stim-vs-pdex →
KTWO K2 Capital Acquisition Corporation Class A Ordinary Share	D+	56/100	—	—	—	+0.20%	$202.2M	/ktwo-vs-pdex →
UTMD Utah Medical Products Inc.	C	62/100	—	57.1%	26.9%	+3.64%	$216.7M	/utmd-vs-pdex →
PROF Profound Medical Corp.	D-	40/100	—	70.8%	-35.0%	+2.44%	$240.0M	/prof-vs-pdex →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000788920 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Pro-Dex Inc. (PDEX) reported GAAP revenue of $66.6M (+23.7% vs. FY2024 revenue of $53.8M , and +44.5% cumulative change since FY2023) , GAAP net income of $9.0M, operating cash flow of -$1.7M, and free cash flow of -$2.9M (-147.0% YoY). On the balance sheet, PDEX closed FY2025 with $62.3M in total assets against $0 in total debt (Altman Z-Score: 9.08, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$66.6M	$9.0M	-$1.7M	-$2.9M	$62.3M	—
FY2024 (FY)	2024-06-30	$53.8M	$2.1M	$6.2M	$6.2M	$60.4M	—
FY2023 (FY)	2023-06-30	$46.1M	$7.1M	$5.5M	$5.5M	—	—

3. PDEX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PDEX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PDEX compare to STIM and KTWO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PDEX?

Where is PDEX trading relative to its 50-day, 200-day, and 52-week technical levels?

PDEX last traded at $57.65 (-0.88% on volume of 63,158 shares), positioning the stock -10.63% below its 50-day simple moving average ($64.51) and +1.60% above its 200-day simple moving average ($56.74). Across its 52-week range of $28.81 to $77.00, PDEX sits at the 59.8% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($52.23 to $63.07).

Direct Sub-Reports: PDEX RQD Cockpit PDEX 12M Forecast PDEX Earnings & Move PDEX Dividends & DRIP PDEX Insiders & 13F PDEX Whale Options PDEX Profit Sankey PDEX News & Why

ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ SEC XBRL & RQD VERIFIED

PDEX — Pro-Dex Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pro-Dex Inc. (PDEX) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $57.65 (-0.88% 1D, market capitalization $186.1M).

Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 23.2%, gross margin of 29.3%, operating margin of 16.1%, and free cash flow yield of -1.47%.
Whale 13F & Options Flow (6/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 9.08, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pro-Dex Inc. (PDEX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The profile describes the company as having a market capitalization of $0.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Pro-Dex Inc. (PDEX) reported $66.6M in annual revenue (up from $53.8M in FY2024, +23.7% YoY) and $9.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.1M revenue, $7.1M net income) through FY2025, PDEX scaled operating cash flow to -$1.7M and free cash flow to -$2.9M, backed by $62.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 54/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -1.47% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $28.81 – $77.00 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 22.2x trailing P/E and 16.5x EV/EBITDA against 16.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), PDEX carries a macro regime beta of 1.00 and gross margin of 29.3%.

Key Question #1: Can PDEX sustain or expand its 16.1% operating margin and 23.2% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $66.6M and free cash flow of -$2.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is PDEX's 18.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PDEX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pro-Dex Inc. (PDEX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PDEX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Pro-Dex, Inc. (PDEX) Q1 Earnings and Revenues Surpass Estimates

Yahoo Finance report covering Pro-Dex Inc. (PDEX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Pro-Dex, Inc. Estimates – NASDAQ:PDEX

TradingView report covering Pro-Dex Inc. (PDEX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

Pro-Dex Inc (PDEX) Reports Q1 FY2027 Earnings: Revenue Hits $20.

GuruFocus report covering Pro-Dex Inc. (PDEX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Gross margin rose to 33% at Pro-Dex (PDEX), but net income went the other way.

Stock Titan report covering Pro-Dex Inc. (PDEX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

ProDex Q1 Earnings Preview: Can Strong Sales Momentum Sustain Growth?

TradingView report covering Pro-Dex Inc. (PDEX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Sales rise 11% at Pro-Dex (PDEX), but earnings move the other way.

Stock Titan report covering Pro-Dex Inc. (PDEX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Pro-Dex Inc. (PDEX) Slips 2.93% to $58.26 as Shares Test Lower End of Recent Range - MESA MA

https://www.dars.gov.et/ report covering Pro-Dex Inc. (PDEX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Pro-Dex (PDEX) unit signs a new industrial lease starting at $11,600 a month.

Stock Titan report covering Pro-Dex Inc. (PDEX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PDEX Bull vs. Bear Conversation Board — What's Your Call at $57.65?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PDEX 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $72.12 (+24.0%)

📌 Pinned Debate

Forensic balance sheet scores 16 of 20 with Altman Z 9.08 and Debt/Equity 0.5, and FY 2025 operating income of $10.7M sits above net in

Here is why I am bullish on PDEX here at $58.16: Forensic balance sheet scores 16 of 20 with Altman Z 9.08 and Debt/Equity 0.5, and FY 2025 operating income of $10.7M sits above net income of $9.0M.. Compare PDEX's 16.1% operating margin and 23.2% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $55.25 are getting bought.

SectorRotator 🐂 BULL

@CashFlowKing Agree on the RQD 54/100 quality, though with 1.0 beta I'm scaling in with half-size at $58.16 and keeping dry powder in case we test $54.09.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $45.95 (-21.0%)

Spot @ $58.16

FY 2025 free cash flow turned negative at -$2.9M and FCF yield is -1.47%, with whale and insider pillars scoring 9 and 10 of 20.

FY 2025 free cash flow turned negative at -$2.9M and FCF yield is -1.47%, with whale and insider pillars scoring 9 and 10 of 20.. Look at the math on PDEX: paying 22.2x trailing P/E for 23.2% ROIC and 16.1% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $51.18 before getting long.